Use access key #2 to skip to page content.
  • S&P 500: 896.42
  • Change: -2.91%
$9.33 -0.45 (-4.60%)
7/2/2009 4:00 PM

Seattle Genetics, Inc. (SGEN)

CAPS Rating:
***

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating SGEN

Add Stock to Watchlist

What the Community Thinks

Total Members

263 Outperforms
24 Underperforms
 

All-Stars

62 Outperforms
12 Underperforms
 

Wall Street

9 Outperforms
0 Underperforms
 

Members bullish on SGEN are also bullish on:

Members bearish on SGEN are also bearish on:

Ticker Tags

Healthcare (770), Rule Breakers Universe (137), Small Cap (1556), Biotechnology (240)
Suggest a tag

Seattle Genetics, Inc. At A Glance

Current Price: $9.33
Last Trade Time: 7/2/2009 4:00 PM
Open: $0.00
Previous Close: $9.78
Daily Range: $9.30 - $9.73
52-Week Range: $6.81 - $13.40
Volume: 00
Market Cap: $837.56M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

SGEN VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Seattle Genetics, Inc. (SGEN)

Avatar TMFBreakerBrian (99.62) Submitted: 3/31/08 1:36 PM

Biopharmaceuticals are being valued at a premium and Seattle Genetics has the goods. Is it the blood cancer biologics version of solid tumor small molecule Exelixis?

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Seattle Genetics, Inc. (SGEN)

Avatar zzlangerhans (99.57) Submitted: 7/24/08 3:20 PM

I have to hand it to the boys from Seattle for keeping their share price up despite a deficiency of late stage trials and a fat burn. Other baby bios in a similar position have had their asses handed to them in this market. But now we're nearing a year high after a sharp upswing on no good news that...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 45 :   1 2 3 4 5 Next »

Recs

0

 (SGEN)

Avatar gokylego (61.90) Submitted: 4/29/09 12:01 AM : Outperform Start Price: $8.98 SGEN Score: 0.07

Partnered well with funding and a intriguing pipeline.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar SpaceMonkey01 (92.21) Submitted: 3/29/09 1:28 PM : Outperform Start Price: $9.61 SGEN Score: -15.56

Moving Average Convergence/Divergence (MACD) indicates a Bullish Trend.
Chart pattern indicates a Strong Upward Trend.
Relative Strength is Bullish.
Up/Down volume pattern indicates that the stock is under Accumulation.
The 50 day Moving Average is rising which is Bullish.
The 200 day Moving Average is rising which is Bullish.
Look for Support at 9.89
Watch for resistance at 10.84

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar Chooseandhold (36.13) Submitted: 11/08/08 3:43 PM : Outperform Start Price: $10.89 SGEN Score: -8.70

Great biotech with a great pipeline and money

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar RNZ100 (91.80) Submitted: 10/08/08 9:28 PM : Outperform Start Price: $8.79 SGEN Score: 15.98

Oversold (but then again, what isn't?!)

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (SGEN)

Avatar zzlangerhans (99.57) Submitted: 7/24/08 4:20 PM : Underperform Start Price: $11.09 SGEN Score: -14.12

I have to hand it to the boys from Seattle for keeping their share price up despite a deficiency of late stage trials and a fat burn. Other baby bios in a similar position have had their asses handed to them in this market. But now we're nearing a year high after a sharp upswing on no good news that I've been able to identify. I think we'll be headed back down again shortly.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 45 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 9 of 9  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackOppenheimer 87.12 10/27/08 Outperform NS $8.28+12.68%+3.84%+8.84
TrackRBCCapMkts 88.51 03/19/08 Outperform NS $8.63+8.11%-33.05%+41.16
TrackMichaelBrus 92.67 02/14/08 Outperform 1Y $9.35-0.21%-33.56%+33.34
TrackJPMorgan 82.92 01/28/08 Outperform NS $9.34-0.11%-32.61%+32.50
TrackFortisBank 94.29 09/21/07 Outperform NS $11.79-20.87%-41.19%+20.32
TrackWMBlair 88.83 08/21/07 Outperform NS $11.03-15.41%-37.92%+22.51
TrackBofASec 95.34 12/12/06 Outperform NS $6.17+51.22%-36.62%+87.83
TrackNeedham 75.83 10/25/06 Outperform NS $4.92+89.63%-34.82%+124.45
TrackNextGen 82.20 10/06/06 Outperform NS $4.95+88.48%-33.41%+121.89

Results 1 - 9 of 9  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 62ms